comlogo01.svg comlogo01.svg

d2imgj1.png

Pipeline

Our pipeline derives from our in-house RDC (Radionuclide Drug Conjugate) discovery capabilities and is comprised of highly differentiated programs.

Cancer Indications
Isotope
Discovery
Preclinical
FIH
Phase I
Phase II
Partnership
PSMA

Prostate Cancer

  • d2icon02-676.svg
Global Rights
NTSR-1

GI Cancers

SCCHN

  • d2icon02-248.svg
fulian2-4.png
SSTR2

NETs

SCLC

  • d2icon02-982.svg
Global Rights
c-MET

NSCLC

GC

  • d2icon02-854.svg
Global Rights
B7H3

SCLC

CRC

  • d2icon02-854.svg
Global Rights
Multiple Early Programs

Cancers

  • d2icon02.svg
Global Rights
PSMA
  • Cancer Indications

    Prostate Cancer

  • Isotope
    • d2icon02-676.svg
  • Partnership
    Global Rights
  • Discovery
  • Preclinical
  • FIH
  • Phase I
  • Phase II
NTSR-1
  • Cancer Indications

    GI Cancers

    SCCHN

  • Isotope
    • d2icon02-248.svg
  • Partnership
    fulian2-4.png
  • Discovery
  • Preclinical
  • FIH
  • Phase I
  • Phase II
SSTR2
  • Cancer Indications

    NETs

    SCLC

  • Isotope
    • d2icon02-982.svg
  • Partnership
    Global Rights
  • Discovery
  • Preclinical
  • FIH
  • Phase I
  • Phase II
c-MET
  • Cancer Indications

    NSCLC

    GC

  • Isotope
    • d2icon02-854.svg
  • Partnership
    Global Rights
  • Discovery
  • Preclinical
  • FIH
  • Phase I
  • Phase II
B7H3
  • Cancer Indications

    SCLC

    CRC

  • Isotope
    • d2icon02-854.svg
  • Partnership
    Global Rights
  • Discovery
  • Preclinical
  • FIH
  • Phase I
  • Phase II
Multiple Early Programs
  • Cancer Indications

    Cancers

  • Isotope
    • d2icon02.svg
  • Partnership
    Global Rights
  • Discovery
  • Preclinical
  • FIH
  • Phase I
  • Phase II

225Ac=Actinium 225

177Lu=Lutetium 177